Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension

Respiratory Medicine

Volumn 101, Issue 11, 2007, Pages 2254-2262

  Suntharalingam, Jay ^a   Goldsmith, Kimberley ^b   Toshner, Mark ^a   Doughty, Natalie ^a   Sheares, Karen K ^a   Hughes, Rodney ^a   Jenkins, David ^a   Pepke Zaba, Joanna ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Natriuretic peptides; Pulmonary endarterectomy; Pulmonary hypertension; Six minute walking distance; Thromboembolism

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDARTERECTOMY; FEMALE; FOLLOW UP; GENDER; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; LUNG HEMODYNAMICS; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REST; RISK ASSESSMENT; SURVIVAL; THROMBOEMBOLISM; WALKING;

AGED; CHRONIC DISEASE; ENDARTERECTOMY; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; PEPTIDE FRAGMENTS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PULMONARY ARTERY; PULMONARY EMBOLISM; TIME FACTORS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 34748920952     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.06.027     Document Type: Article

References (40)

1. Hoeper M.M., Mayer E., Simonneau G., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. Circulation 113 16 (2006) 2011-2020
2. Riedel M., Stanek V., Widimsky J., and Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81 2 (1982) 151-158
3. Jamieson S.W., Kapelanski D.P., Sakakibara N., Manecke G.R., Thistlethwaite P.A., Kerr K.M., et al. Pulmonary endarterectomy: experience and lessons learned in 1500 cases. Ann Thorac Surg 76 5 (2003) 1457-1462 discussion 1462-4
4. Kim N.H. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 7 (2006) 584-588
5. Thistlethwaite P.A., Mo M., Madani M.M., Deutsch R., Blanchard D., Kapelanski D.P., et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 124 6 (2002) 1203-1211
6. Bresser P., Pepke-Zaba J., Jais X., Humbert M., and Hoeper M.M. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 3 7 (2006) 594-600
7. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 4 (1991) 1402-1412
8. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 3 (2002) 161-167
9. Tsutamoto T., Wada A., Maeda K., Hisanaga T., Maeda Y., Fukai D., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 2 (1997) 509-516
10. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 8 (2000) 865-870
11. Leuchte H.H., Holzapfel M., Baumgartner R.A., Ding I., Neurohr C., Vogeser M., et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43 5 (2004) 764-770
12. Leuchte H.H., Holzapfel M., Baumgartner R.A., Neurohr C., Vogeser M., and Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 128 4 (2005) 2368-2374
13. Park M.H., Scott R.L., Uber P.A., Ventura H.O., and Mehra M.R. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. Congest Heart Fail 10 5 (2004) 221-225
14. Nagaya N., Ando M., Oya H., Ohkita Y., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 74 1 (2002) 180-184 discussion 184
15. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (London) 97 3 (1999) 255-258
16. Yeo K.T., Wu A.H., Apple F.S., Kroll M.H., Christenson R.H., Lewandrowski K.B., et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338 1-2 (2003) 107-115
17. Andreassen A.K., Wergeland R., Simonsen S., Geiran O., Guevara C., and Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98 4 (2006) 525-529
18. Fijalkowska A., Kurzyna M., Torbicki A., Szewczyk G., Florczyk M., Pruszczyk P., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 5 (2006) 1313-1321
19. Souza R., Bogossian H.B., Humbert M., Jardim C., Rabelo R., Amato M.B., et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 25 3 (2005) 509-513
20. Williams M.H., Handler C.E., Akram R., Smith C.J., Das C., Smee J., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 12 (2006) 1485-1494
21. Gan C.T., McCann G.P., Marcus J.T., van Wolferen S.A., Twisk J.W., Boonstra A., et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 28 6 (2006) 1190-1194
22. Doyle R.L., McCrory D., Channick R.N., Simonneau G., and Conte J. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl. (2004) 63S-71S
23. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl. S (2004) 5S-12S
24. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 1 (2002) 111-117
25. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130 6 (1999) 461-470
26. Menzel T., Wagner S., Kramm T., Mohr-Kahaly S., Mayer E., Braeuninger S., et al. Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: changes after pulmonary thromboendarterectomy. Chest 118 4 (2000) 897-903
27. Dartevelle P., Fadel E., Mussot S., Chapelier A., Herve P., de Perrot M., et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 23 4 (2004) 637-648
28. Hartz R.S., Byrne J.G., Levitsky S., Park J., and Rich S. Predictors of mortality in pulmonary thromboendarterectomy. Ann Thorac Surg 62 5 (1996) 1255-1259 discussion 1259-60
29. Raymond I., Groenning B.A., Hildebrandt P.R., Nilsson J.C., Baumann M., Trawinski J., et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89 7 (2003) 745-751
30. Das S.R., Drazner M.H., Dries D.L., Vega G.L., Stanek H.G., Abdullah S.M., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112 14 (2005) 2163-2168
31. Sayama H., Nakamura Y., Saito N., and Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?. Coron Artery Dis 10 7 (1999) 537-540
32. Giannessi D., Andreassi M.G., Del Ry S., Clerico A., Colombo M.G., and Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 24 1 (2001) 8-16
33. Arbab-Zadeh A., Dijk E., Prasad A., Fu Q., Torres P., Zhang R., et al. Effect of aging and physical activity on left ventricular compliance. Circulation 110 13 (2004) 1799-1805
34. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Corey D., Leip E.P., et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108 1 (2003) 13-16
35. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 2, pt 1 (2000) 487-492
36. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 4 (2002) 780-788
37. Oudiz R.J., Barst R.J., Hansen J.E., Sun X.G., Garofano R., Wu X., et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 97 1 (2006) 123-126
38. Matsuda H., Ogino H., Minatoya K., Sasaki H., Nakanishi N., Kyotani S., et al. Long-term recovery of exercise ability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 82 4 (2006) 1338-1343 discussion 1343
39. D'Armini A.M., Cattadori B., Monterosso C., Klersy C., Emmi V., Piovella F., et al. Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension: hemodynamic characteristics and changes. Eur J Cardiothorac Surg 18 6 (2000) 696-701 discussion 701-2
40. Zoia M.C., D'Armini A.M., Beccaria M., Corsico A., Fulgoni P., Klersy C., et al. Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status. Thorax 57 7 (2002) 608-612